Research and Markets has announced the addition of the "Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Pipeline Review, H2 2016" report to their offering.

The report provides comprehensive information on the Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics development and features dormant and discontinued projects.

Key Topics Covered:

Introduction

  1. Cathepsin K Overview
  2. Therapeutics Development
  3. Pipeline Products for Cathepsin K - Overview
  4. Pipeline Products for Cathepsin K - Comparative Analysis
  5. Cathepsin K - Therapeutics under Development by Companies
  6. Cathepsin K - Therapeutics under Investigation by Universities/Institutes
  7. Cathepsin K Products Glance
  8. Late Stage Products
  9. Clinical Stage Products
  10. Early Stage Products
  11. Cathepsin K - Products under Development by Companies
  12. Cathepsin K - Products under Investigation by Universities/Institutes
  13. Cathepsin K - Companies Involved in Therapeutics Development

- Amura Holdings Ltd

- Medivir AB

- Sanofi

- Virobay Inc

- Wroclawskie Centrum Badan EIT+ Sp z oo

For more information about this report visit http://www.researchandmarkets.com/research/djrdxb/cathepsin_k